SCHEMBL6789147

SCHEMBL6789147

CCCCCCN(C)c1ccc(/C=C2\SC(=S)N(CCNS(=O)(=O)c3ccccc3)C2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ PAX8 Q06710 1/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ POLB P06746 3/20 0.44
▸ HPGD P15428 1/20 0.44
▸ CRHBP P24387 2/20 0.44
▸ CRHR2 Q13324 2/20 0.44
▸ MAOA P21397 2/20 0.43
▸ MAOB P27338 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CISD1 Q9NZ45 2/20 0.43
▸ DNM1 Q05193 1/20 0.42
▸ FAAH O00519 1/20 0.42
▸ BCL2 P10415 1/20 0.41
▸ AKR1B1 P15121 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789151 1.00 KMT2A (0.50) KMT2ANPSR1RXFP1PAX8MEN1
SCHEMBL6786775 0.89 ALDH1A1 (0.47) KMT2APAX8MEN1POLBHPGD
SCHEMBL6903986 0.86 ALDH1A1 (0.44) KMT2APAX8MEN1POLBHPGD
SCHEMBL7060689 0.86 ALDH1A1 (0.44) KMT2APAX8MEN1POLBHPGD
SCHEMBL6785574 0.85 KMT2A (0.51) KMT2ANPSR1RXFP1MEN1POLB
SCHEMBL6792437 0.85 KMT2A (0.51) KMT2ANPSR1RXFP1MEN1POLB
SCHEMBL6785608 0.82 ALDH1A1 (0.47) KMT2ANPSR1RXFP1PAX8MEN1
SCHEMBL6792827 0.82 MYC (0.50) KMT2APAX8POLBMAOAMAOB
SCHEMBL6792830 0.82 MYC (0.50) KMT2APAX8POLBMAOAMAOB
SCHEMBL6785606 0.82 ALDH1A1 (0.47) KMT2ANPSR1RXFP1PAX8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 KMT2A 4348/4885NPSR1 1053/4885RXFP1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback